Want to see OFIX full AI Analyst Report?
OFIX Stock Chart & Stats
$12.01
-$0.08(-0.47%)
At close: 4:00 PM EST
$12.01
-$0.08(-0.47%)
Day’s Range― - ―
52-Week Range$8.85 - $16.99
Previous CloseN/A
Volume45.16K
Average Volume (3M)212.06K
Market Cap
$470.10M
Enterprise Value$487.20M
Total Cash (Recent Filing)$120.28M
Total Debt (Recent Filing)$234.39M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 11, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding40,421,654
10 Day Avg. Volume220,565
30 Day Avg. Volume212,061
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.34
Price to Sales (P/S)0.74
P/FCF Ratio-472.73
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue0.59
Enterprise Value/Gross Profit0.86
Enterprise Value/Ebitda5.16
Forecast
1Y Price Target
$15.50Price Target Upside29.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.16
Revenue Forecast (FY)$843.71M
Bulls Say, Bears Say
Bulls Say
Scale & Margin ProfileOrthofix has a durable revenue base and high gross margins that provide structural leverage as volumes grow. Positive operating cash flow (~$35M TTM) shows improving cash conversion, giving the company capacity to fund launches and commercial execution while pursuing margin expansion over the next 2–6 months.
Innovation Pipeline & Launch CadenceA defined pipeline (VIRATA, TrueLok Elevate, Fitbone, 7D/FLASH navigation) creates multi-quarter tailwinds to product mix and surgeon adoption. Durable product differentiation and scheduled launches support higher ASPs and recurring procedure-based revenue, underpinning sustainable top-line and margin improvement if execution holds.
Reimbursement Risk MitigationRestoration of Medicare reimbursement removes a key structural policy overhang for bone-growth stimulators, stabilizing payor coverage and near-term revenue visibility. This materially reduces downside risk to the device franchise and supports management’s ability to execute on FY guidance and multi-product commercialization plans.
Bears Say
Negative ProfitabilityDespite solid revenue and gross margin, the company remains loss-making at the EBIT and net levels. Persistent negative margins limit retained earnings, depress return on equity, and constrain the firm’s ability to self-fund strategic initiatives absent sustained margin improvement or continued external financing.
Weak Free Cash Flow GenerationFree cash flow remains marginally negative, indicating cash conversion is not yet consistently robust. This constrains reinvestment and increases reliance on financing (including recent draws), making the company vulnerable to shocks—especially if legal settlements or working capital swings occur over the next several quarters.
Product/Execution Headwinds (Biologics)Underperformance in biologics and some limb-reconstruction areas reflects structural execution and adoption gaps. These franchise-level weaknesses, plus prior catalogue sunsetting and distributor transition effects, imply that growth depends on operational fixes and commercial execution that may take multiple quarters to fully materialize.
Orthofix Medical News
OFIX FAQ
What was Orthofix Medical’s price range in the past 12 months?
Orthofix Medical lowest stock price was $8.85 and its highest was $16.99 in the past 12 months.
What is Orthofix Medical’s market cap?
Orthofix Medical’s market cap is $470.10M.
When is Orthofix Medical’s upcoming earnings report date?
Orthofix Medical’s upcoming earnings report date is Aug 11, 2026 which is in 28 days.
How were Orthofix Medical’s earnings last quarter?
Orthofix Medical released its earnings results on May 05, 2026. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.68 by $0.16.
Is Orthofix Medical overvalued?
According to Wall Street analysts Orthofix Medical’s price is currently Undervalued.
Does Orthofix Medical pay dividends?
Orthofix Medical does not currently pay dividends.
What is Orthofix Medical’s EPS estimate?
Orthofix Medical’s EPS estimate is -0.4.
How many shares outstanding does Orthofix Medical have?
Orthofix Medical has 40,421,654 shares outstanding.
What happened to Orthofix Medical’s price movement after its last earnings report?
Orthofix Medical reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.68. Following the earnings report the stock price went up 3.58%.
Which hedge fund is a major shareholder of Orthofix Medical?
Currently, no hedge funds are holding shares in OFIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orthofix Medical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.50 (29.06% Upside)
$15.50 (29.06% Upside)
Blogger Sentiment
Neutral
OFIX Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 30.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.13%
12-Months-Change
Fundamentals
Return on Equity
-13.44%
Trailing 12-Months
Asset Growth
7.71%
Trailing 12-Months
Company Description
Orthofix Medical
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
OFIX Stock 12 Month Forecast
Average Price Target
$15.50
▲(29.06% Upside)
Technical Analysis
Ownership Overview
25.94% Insiders
12.58% Mutual Funds
0.19% Other Institutional Investors
47.91% Public Companies and
Individual Investors








